Which Frontline EGFR TKI Should be Used in NSCLC?

Clinical Pearls

Lecia V. Sequist, MD, medical oncologist, associate professor, Massachusetts General Hospital, Harvard Medical School, discusses the unanswered question of which EGFR TKI to use in the frontline setting of NSCLC.

• Patients with EGFR-mutated NSCLC should preferentially receive an EGFR TKI, not chemotherapy.
• It is still unknown which EGFR TKI should be administered first.
• A trial is underway comparing gefitinib with afatinib in the frontline setting.